The effect of Montelukast on COVID 19 disease activity
Phase 3
Recruiting
- Conditions
- COVID-19.COVID-19, virus identifiedU07.1
- Registration Number
- IRCT20181208041886N3
- Lead Sponsor
- Abidi Pharmaceutical company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Every patient with diagnosis of COVID-19
Mild, moderate and severe stage of the disease
Exclusion Criteria
No complete consent and compliace of the patient for study
Follow up of the patient not be possible
The age below 15 years old
Rifampin and Phenobarbital consumers
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Discontinuation of fever. Timepoint: Daily till 14 days. Method of measurement: Measurement of temperature by digital infrared thermometer, and the O2 saturation by pulseoximeter.;Decreased Respiratory Rate. Timepoint: Daily till 14 days. Method of measurement: Measurement of fever by a termometer, and O2 saturation by pulse Oximetery.;Decreased Cough. Timepoint: Daily till 14 days. Method of measurement: Body temperature by thermometer, O2 sat by pulseoximetery.;Evaluation of blood O2 Saturation. Timepoint: Daily till 14 days. Method of measurement: Physician evaluation by Puls oxymetery.
- Secondary Outcome Measures
Name Time Method Improvement of the patient with diagnosis of COVID-19 infection. Timepoint: Daily till 14 days. Method of measurement: Evaluation by Physician.